Compare IBRX & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | HIMS |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.9B |
| IPO Year | 2015 | 2019 |
| Metric | IBRX | HIMS |
|---|---|---|
| Price | $8.72 | $28.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 15 |
| Target Price | $12.57 | ★ $30.46 |
| AVG Volume (30 Days) | ★ 9.0M | 8.1M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $113,288,000.00 | ★ $2,347,637,000.00 |
| Revenue This Year | $88.59 | $19.82 |
| Revenue Next Year | $131.15 | $19.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 668.31 | 59.00 |
| 52 Week Low | $1.95 | $13.74 |
| 52 Week High | $12.43 | $65.30 |
| Indicator | IBRX | HIMS |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 48.18 |
| Support Level | $6.68 | $27.36 |
| Resistance Level | $9.54 | $30.10 |
| Average True Range (ATR) | 0.54 | 1.50 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 57.88 | 37.99 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.